{"id":173447,"date":"2026-01-22T10:00:58","date_gmt":"2026-01-22T15:00:58","guid":{"rendered":"https:\/\/alphastreet.com\/india\/jeena-sikho-lifecare-ltd-jsll-q2-2025-earnings-call-transcript\/"},"modified":"2026-01-22T10:00:58","modified_gmt":"2026-01-22T15:00:58","slug":"jeena-sikho-lifecare-ltd-jsll-q2-2025-earnings-call-transcript","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/jeena-sikho-lifecare-ltd-jsll-q2-2025-earnings-call-transcript\/","title":{"rendered":"Jeena Sikho Lifecare Ltd (JSLL) Q2 2025 Earnings Call Transcript"},"content":{"rendered":"

Jeena Sikho Lifecare Ltd (NSE: JSLL) Q2 2025 Earnings Call dated Nov. 13, 2024<\/span><\/strong><\/p>\n

Corporate Participants:<\/h2>\n

Manish Grover<\/strong> \u2014 Managing Director<\/em><\/p>\n

Nanak Chand<\/strong> \u2014 Chief Financial Officer<\/em><\/p>\n

Analysts:<\/h2>\n

Ranvir Singh<\/strong> \u2014 Analyst<\/em><\/p>\n

Sagar Jain<\/strong> \u2014 Individual Investor<\/em><\/p>\n

Sumit Gupta<\/strong> \u2014 |Analyst<\/em><\/p>\n

Chirag Shah<\/strong> \u2014 Analyst<\/em><\/p>\n

Yash Gandhi<\/strong> \u2014 Analyst<\/em><\/p>\n

Prerana Amanna<\/strong> \u2014 Analyst<\/em><\/p>\n

K Rajesh<\/strong> \u2014 Individual Investor<\/em><\/p>\n

Nishant Gupta<\/strong> \u2014 Analyst<\/em><\/p>\n

Anurag Agrawal<\/strong> \u2014 Analyst<\/em><\/p>\n

Akshay Kaila<\/strong> \u2014 Analyst<\/em><\/p>\n

Isha Agarwal<\/strong> \u2014 Analyst<\/em><\/p>\n

Priyam Khimawat<\/strong> \u2014 Analyst<\/em><\/p>\n

Amit Jeswani<\/strong> \u2014 Analyst<\/em><\/p>\n

Nitin Gupta<\/strong> \u2014 Individual Investor<\/em><\/p>\n

Presentation:<\/h2>\n

Operator<\/strong><\/p>\n

Ladies and gentlemen, good day, and welcome to the Jeena Sikho Lifecare Limited H1 FY25 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. [Operator Instructions].<\/p>\n

Please note that this conference is being recorded. I now hand the conference over to Mr. Ranvir Singh from Nuvama Wealth. Thank you, and over to you, sir.<\/p>\n

Ranvir Singh<\/strong> \u2014 Analyst<\/em><\/p>\n

Thank you, moderator. On behalf of Jeena Sikho Lifecare Limited, I extend a very warm welcome to all participants on H1 FY25 financial results discussion call. Today on our call, we have Mr. Manish Grover Ji, Managing Director; and Mr. Nanak Chand Ji, the CFO.<\/p>\n

Before beginning with this call, I would like to give a short disclaimer. This call may contain some of the forward-looking statements which are completely based upon the management’s beliefs, opinions, and expectations as of today. These statements are not a guarantee of the company’s future performance and involve unforeseen risk and uncertainty.<\/p>\n

With this, I would have to hand over the call to Mr. Manish Ji for his opening remarks. Over to you, sir. Manish, sir?<\/p>\n

Manish Grover<\/strong> \u2014 Managing Director<\/em><\/p>\n

[Foreign Speech].<\/p>\n

Nanak Chand<\/strong> \u2014 Chief Financial Officer<\/em><\/p>\n

Good afternoon, everyone. Thank you, Manish sir. As mentioned by Manish sir, we have achieved the healthy financial performance during the H1 FY25. Here are some key highlights. We generated revenue from operations and grew by 36% on year-on-year basis to INR214 crores, mainly driven by the hospital services, which has grew by 72%,Y-o-Y basis raised INR114 crores.<\/p>\n

While product sales grew by 10% to INR100 crores, the EBITDA during the H1 FY25 grew by 32%, Y-o-Y basis to INR59.28 crores by implementing the EBITDA margin 28%. The H1 FY25 PAT grew by 47% Y-o-Y basis to INR46.88 crores. We retain a healthy balance sheet with net cash and equivalent of INR69 crores by end of the H1 FY25. Our ex-cash ROCE stood 82% respectively. And we also spent the INR16.72 crores in capex in H1 FY25.<\/p>\n

Thank you so much.<\/p>\n

Operator<\/strong><\/p>\n

Sir, should we open the floor for questions?<\/p>\n

Nanak Chand<\/strong> \u2014 Chief Financial Officer<\/em><\/p>\n

Sir, you can open floor for questions.<\/p>\n

Questions and Answers:<\/h2>\n

Operator<\/strong><\/p>\n

Thank you very much. We will now begin the question-and-answer session. [Operator Instructions]. Our first question comes from Sagar Jain, Individual Investor. Please go ahead.<\/p>\n

Sagar Jain<\/strong><\/p>\n

Hi, thanks for giving me the opportunity. Congratulations, Manish and Nanak for posting the very good results. However, I just have one question regarding the expansion that you are expanding to the 21 states of India and you have already crossed more than 100 towns of India.<\/p>\n

So I just want to know that how this revenue is being generated majorly from the few hospitals or is evenly distributed, how it is coming from few locations of India or it is coming from every part of the 100 hospitals or maybe hospitals in 100 towns is coming from? So, how it is distributed?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Sagar Jain<\/strong><\/p>\n

Yes, sir. Really thanks, sir. Even I am also a diabetic patient, so I definitely wish to —<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Sagar Jain<\/strong><\/p>\n

Absolutely, sir. Thanks, sir. I can see you and team are very aggressively trying to expand your business. Thank you. Thank you very much.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question comes from Sumit Gupta from Centrum. Please go ahead.<\/p>\n

Sumit Gupta<\/strong><\/p>\n

Hi, thank you for the opportunity, sir. I have two questions. First is on the hospital side. So, the kind of extension that you are going to do, just want to understand on the doctor cost point. So, how many doctors do you plan to — like, in overall doctor strength how much do you plan to increase and [Foreign Speech] overall?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Sumit Gupta<\/strong><\/p>\n

Understood, sir. And sir, going forward, like I am seeing from FY23, your government revenue as percentage of overall revenue it has increased from 12% to 24%, which is double. So, going forward also, what kind of government empanelment do you see?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Sumit Gupta<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Sumit Gupta<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Sumit Gupta<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Sumit Gupta<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Sumit Gupta<\/strong><\/p>\n

Okay sir, understood.<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Sumit Gupta<\/strong><\/p>\n

Okay sir, understood<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Sumit Gupta<\/strong><\/p>\n

Yes sir.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question comes from Chirag from White Pine. Please go ahead. Chirag, your line is unmuted. Please proceed with your question.<\/p>\n

Chirag Shah<\/strong><\/p>\n

Namaskar Acharya ji, [Foreign Speech].?<\/p>\n

Manish Grover<\/strong><\/p>\n

Namaskar Chirag ji, [Foreign Speech].?<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

Okay.<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

Okay. [Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

Okay, okay.<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Chirag Shah<\/strong><\/p>\n

[Foreign Speech]. Sir, all the best. I will come back for more questions.<\/p>\n

Manish Grover<\/strong><\/p>\n

Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question comes from Yash from Stallion Asset. Please go ahead.<\/p>\n

Yash Gandhi<\/strong><\/p>\n

Hi, Manish Ji. Thank you again for the opportunity. Manish Ji, [Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Yash Gandhi<\/strong><\/p>\n

Okay, okay. Thank you. [Foreign Speech]. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question comes from Prerana from Shome Partnership Limited. Please go ahead.<\/p>\n

Prerana Amanna<\/strong><\/p>\n

Yeah. Hello, sir. Congratulations for a good set of numbers. [Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Prerana Amanna<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

.<\/p>\n

Prerana Amanna<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Prerana Amanna<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Prerana Amanna<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Prerana Amanna<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Prerana Amanna<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Nanak Chand<\/strong><\/p>\n

Volume growth in medicine has increased by 10%. And in the service sectors, it has increased by 42% to 53%. In which way volume —<\/p>\n

Prerana Amanna<\/strong><\/p>\n

Okay. Sir, this is the last question. [Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Prerana Amanna<\/strong><\/p>\n

Okay. [Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Prerana Amanna<\/strong><\/p>\n

All the best, sir. All the best.<\/p>\n

Manish Grover<\/strong><\/p>\n

Okay. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question comes from K Rajesh, an Individual Investor. Please go ahead.<\/p>\n

K Rajesh<\/strong><\/p>\n

Good afternoon, Manish sir. Hello?<\/p>\n

Manish Grover<\/strong><\/p>\n

Ji, Namaskar.<\/p>\n

K Rajesh<\/strong><\/p>\n

Namaskar Ji. Sir, congratulations for a very good set of numbers. And I think, we are going as per —<\/p>\n

Operator<\/strong><\/p>\n

Mr. Rajesh, you are sounding a bit muffled. If you can use the handset, please?<\/p>\n

K Rajesh<\/strong><\/p>\n

Yes. Hello?<\/p>\n

Operator<\/strong><\/p>\n

Yes, sir.<\/p>\n

Manish Grover<\/strong><\/p>\n

Ji, namaskar sir.<\/p>\n

K Rajesh<\/strong><\/p>\n

Namaskar, sir. Sir, I think as per the numbers, we are going as per the guidance of INR450 crores. Can we expect INR1,000 crores revenue in FY26, sir? As per the bed occupancy, it is also increasing?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

K Rajesh<\/strong><\/p>\n

Sir, what about the main board plan? Are they going or not?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

K Rajesh<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

K Rajesh<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

Dubai, Vietnam, Mauritius, London, America, Australia, New Zealand, [Foreign Speech].<\/p>\n

K Rajesh<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

K Rajesh<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

K Rajesh<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

K Rajesh<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

K Rajesh<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

K Rajesh<\/strong><\/p>\n

[Foreign Speech]. Thank you, sir. Thank you for the results. Okay.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question comes from Nishant Gupta from Minerva Global Capital. Please go ahead.<\/p>\n

Nishant Gupta<\/strong><\/p>\n

Sir, thank you. [Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Nishant Gupta<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Nishant Gupta<\/strong><\/p>\n

Got it. [Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Nishant Gupta<\/strong><\/p>\n

Got it, sir. [Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Nishant Gupta<\/strong><\/p>\n

Okay. Thank you, sir.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question is from Anurag Agrawal from Multify Wealth. Please go ahead.<\/p>\n

Anurag Agrawal<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Anurag Agrawal<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Anurag Agrawal<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Anurag Agrawal<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Anurag Agrawal<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Anurag Agrawal<\/strong><\/p>\n

Right. Okay. Thank you for the information, Acharya Ji.<\/p>\n

Manish Grover<\/strong><\/p>\n

Ji.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question comes from Akshay from CD Integrated Services Limited. Please go ahead.<\/p>\n

Akshay Kaila<\/strong><\/p>\n

Hello, sir. Am I audible?<\/p>\n

Manish Grover<\/strong><\/p>\n

Ji Namaskar.<\/p>\n

Akshay Kaila<\/strong><\/p>\n

Namaskar, sir. [Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Akshay Kaila<\/strong><\/p>\n

Okay, sir. [Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

Yes, sir. [Foreign Speech].<\/p>\n

Akshay Kaila<\/strong><\/p>\n

Okay, right, sir. [Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Akshay Kaila<\/strong><\/p>\n

Okay, sir. [Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Akshay Kaila<\/strong><\/p>\n

Okay, sir. Okay. Thank you so much, sir. It was helpful.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. [Operator Instructions]. The next question comes from Isha from VT Capital. Please go ahead. Isha, your line is unmuted. Please proceed with your question.<\/p>\n

Isha Agarwal<\/strong><\/p>\n

Yes, good afternoon, Acharya Ji.<\/p>\n

Manish Grover<\/strong><\/p>\n

Ji, Namaskar.<\/p>\n

Isha Agarwal<\/strong><\/p>\n

Congratulations on a very good set of numbers.<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Operator<\/strong><\/p>\n

Isha ma’am, can you please use the handset?<\/p>\n

Isha Agarwal<\/strong><\/p>\n

Hello?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Isha Agarwal<\/strong><\/p>\n

Congratulations on a good set of numbers. [Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Isha Agarwal<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Isha Agarwal<\/strong><\/p>\n

Okay. Thank you so much.<\/p>\n

Manish Grover<\/strong><\/p>\n

Okay, ma’am. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

The next question comes from Priyam Khimawat from Ask Investment Managers. Please go ahead.<\/p>\n

Priyam Khimawat<\/strong><\/p>\n

Namaskar, Acharya ji.<\/p>\n

Manish Grover<\/strong><\/p>\n

Ji, Namaskar.<\/p>\n

Priyam Khimawat<\/strong><\/p>\n

Acharya ji, [Foreign Speech]. So which is the best-selling therapy? Is it kidney? Is it liver? What is it?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Priyam Khimawat<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Priyam Khimawat<\/strong><\/p>\n

Got it, got it. [Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Priyam Khimawat<\/strong><\/p>\n

On an average, if a doctor is having 10-year or five-year experience, what kind of annual income do they make?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Priyam Khimawat<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Priyam Khimawat<\/strong><\/p>\n

Okay, sir. Got it, got it. All the best, Acharya Ji. You’re doing great job. Congratulations and continue doing the great job going ahead. Thank you.<\/p>\n

Manish Grover<\/strong><\/p>\n

Thank you. [Foreign Speech].<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question comes from Amit Jeswani from Stallion Asset Private Limited. Please go ahead.<\/p>\n

Amit Jeswani<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Amit Jeswani<\/strong><\/p>\n

All good. Thank you.<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Amit Jeswani<\/strong><\/p>\n

Thank you so much Manish Ji. [Foreign Speech]? I have no doubt on your capabilities but [Foreign Speech]? Still how are you managing your time?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Amit Jeswani<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Amit Jeswani<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Amit Jeswani<\/strong><\/p>\n

In the Ayurveda medicine business?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Amit Jeswani<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Manish Grover<\/strong><\/p>\n

Thank you, sir.<\/p>\n

Amit Jeswani<\/strong><\/p>\n

Thank you. Thank you so much.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question comes from Akshay from CD Integrated Services Limited. Please go ahead.<\/p>\n

Akshay Kaila<\/strong><\/p>\n

Hello, sir. [Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Akshay Kaila<\/strong><\/p>\n

Okay, sir. Okay.<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Akshay Kaila<\/strong><\/p>\n

Right. Right, sir. Okay, sir. [Foreign Speech]. Thank you, sir. And all the best for the future, sir.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question comes from Nitin Gupta, an Individual Investor. Please go ahead.<\/p>\n

Nitin Gupta<\/strong><\/p>\n

Hello? Am I audible?<\/p>\n

Manish Grover<\/strong><\/p>\n

Ji, Namaskar, sir.<\/p>\n

Nitin Gupta<\/strong><\/p>\n

Namaskar, Manish Ji. [Foreign Speech]. To fund those expansions, do you have any plan to raise funds in the future? Or everything can be funded by internal approvals?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Nitin Gupta<\/strong><\/p>\n

[Foreign Speech]?<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech].<\/p>\n

Nitin Gupta<\/strong><\/p>\n

[Foreign Speech]. Okay. That’s all from my side. Thank you.<\/p>\n

Manish Grover<\/strong><\/p>\n

Thank you, sir.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. As there are no further questions from the participants, I now hand the conference over to the management for closing comments. Manish sir, you can give the closing remarks if there are any.<\/p>\n

Manish Grover<\/strong><\/p>\n

[Foreign Speech]. Thank you very much. [Foreign Speech]. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

[Operator Closing Remarks].<\/p>\n","protected":false},"excerpt":{"rendered":"

Jeena Sikho Lifecare Ltd (NSE: JSLL) Q2 2025 Earnings Call dated Nov. 13, 2024 Corporate Participants: Manish Grover \u2014 Managing Director Nanak Chand \u2014 Chief Financial Officer Analysts: Ranvir Singh \u2014 Analyst Sagar Jain \u2014 Individual Investor Sumit Gupta \u2014 |Analyst Chirag Shah \u2014 Analyst Yash Gandhi \u2014 Analyst Prerana Amanna \u2014 Analyst K Rajesh […]<\/p>\n","protected":false},"author":2377,"featured_media":147581,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[6349],"tags":[10169,9175,9104,9092,14492,10089],"class_list":["post-173447","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-transcripts","tag-earnings","tag-earnings-call","tag-earnings-conference","tag-earnings-transcripts","tag-financial-results","tag-quarterly-earnings"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":181549,"url":"https:\/\/alphastreet.com\/india\/jeena-sikho-lifecare-ltd-jsll-q3-2026-earnings-call-transcript\/","url_meta":{"origin":173447,"position":0},"title":"Jeena Sikho Lifecare Ltd (JSLL) Q3 2026 Earnings Call Transcript","author":"News desk","date":"April 8, 2026","format":false,"excerpt":"Jeena Sikho Lifecare Ltd (NSE: JSLL) Q3 2026 Earnings Call dated Feb. 09, 2026 Corporate Participants: Manish Groverji \u2014 Managing Director Nanak Chand \u2014 Chief Financial Officer Analysts: Ranvir Singh \u2014 Analyst Priyanshu Jain \u2014 Analyst Akshay Kaila \u2014 Analyst Abhishek Sengupta \u2014 Analyst Akhilesh Rawat \u2014 Analyst Unidentified Participant\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":170237,"url":"https:\/\/alphastreet.com\/india\/jeena-sikho-life-care-q1-fy26-earnings-results\/","url_meta":{"origin":173447,"position":1},"title":"Jeena Sikho Life Care Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 15, 2025","format":false,"excerpt":"Jeena Sikho Lifecare Limited is one of the leading providers of ayurvedic healthcare systems in India, delivering healthcare services for over a decade. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b93,401 crore, up 4.23% year-on-year (YoY) from \u20b93,263 crore in Q1 FY25. Total Expenses:\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"JSLL Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JSLL.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JSLL.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JSLL.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JSLL.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JSLL.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JSLL.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":180003,"url":"https:\/\/alphastreet.com\/india\/jeena-sikho-lifecare-limited-reports-sharp-q3-fy26-growth-as-revenue-and-profit-surge\/","url_meta":{"origin":173447,"position":2},"title":"Jeena Sikho Lifecare Limited reports sharp Q3 FY26 growth as revenue and profit surge","author":"Staff Correspondent","date":"February 9, 2026","format":false,"excerpt":"Jeena Sikho Lifecare Limited (NSE: JSLL, BSE: 544476) reported strong financial and operating performance for the quarter ended December 31, 2025, driven by rapid expansion across its Ayurveda healthcare services and products businesses, according to the company\u2019s Q3 FY26 investor presentation. Financial performance Revenue from operations rose to \u20b9221.66 crore\u2026","rel":"","context":"In "LATEST"","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":173446,"url":"https:\/\/alphastreet.com\/india\/jeena-sikho-lifecare-ltd-jsll-q4-2025-earnings-call-transcript\/","url_meta":{"origin":173447,"position":3},"title":"Jeena Sikho Lifecare Ltd (JSLL) Q4 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Jeena Sikho Lifecare Ltd (NSE: JSLL) Q4 2025 Earnings Call dated May. 20, 2025 Corporate Participants: Manish Grover \u2014 Managing Director Nanak Chand \u2014 Chief Financial Officer Analysts: Ranvir Singh \u2014 Analyst Agastya Dave \u2014 Analyst Abhishek \u2014 Analyst Akshay Kaila \u2014 Analyst Naveen Baid \u2014 Analyst Prerana Nireeksha Amanna\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":41715,"url":"https:\/\/alphastreet.com\/india\/wipro-limited-wit-q2-2020-earnings-snapshot\/","url_meta":{"origin":173447,"position":4},"title":"Wipro Limited (WIT): Q2 2020 Earnings Snapshot","author":"Toby","date":"October 15, 2019","format":false,"excerpt":"-- Wipro Limited (NYSE: WIT) reported second-quarter 2020 earnings of $0.06 per share, in line with Wall Street projection -- Revenues grew 4% to $2.14 billion, vs. $2.13 billion expected. -- In Q2, IT Services revenue grew 2.5% to $2.05 billion. -- Wipro expects IT Services revenue to be $2.065\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"Earnings Update by AlphaStreet","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-Coverage-5.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-Coverage-5.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-Coverage-5.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-Coverage-5.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-Coverage-5.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":109778,"url":"https:\/\/alphastreet.com\/india\/infosys-limited-infy-q4-2021-earnings-call\/","url_meta":{"origin":173447,"position":5},"title":"Infosys Limited (INFY) Q4 2021 Earnings Call","author":"Sahil Anand","date":"April 21, 2021","format":false,"excerpt":"Infosys Limited (NYSE: INFY) Q4 2021 earnings call dated\u00a0Apr. 14, 2021 Corporate Participants: Sandeep Mahindroo\u00a0\u2014\u00a0Vice President, Financial Controller & Head \u2013 Investor Relations Salil Parekh\u00a0\u2014\u00a0Chief Executive Officer and Managing Director Pravin Rao\u00a0\u2014\u00a0Chief Operating Officer and Whole-time Director Nilanjan Roy\u00a0\u2014\u00a0Chief Financial Officer Analysts: Ankur Rudra\u00a0\u2014\u00a0JPMorgan \u2014 Analyst Diviya Nagarajan\u00a0\u2014\u00a0UBS \u2014 Analyst\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/04\/Infosys-Limited-Q4-2021-Earnings-Call.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/04\/Infosys-Limited-Q4-2021-Earnings-Call.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/04\/Infosys-Limited-Q4-2021-Earnings-Call.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/04\/Infosys-Limited-Q4-2021-Earnings-Call.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/04\/Infosys-Limited-Q4-2021-Earnings-Call.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/04\/Infosys-Limited-Q4-2021-Earnings-Call.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/173447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2377"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=173447"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/173447\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/147581"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=173447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=173447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=173447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}